Destiny Pharma participates in the launch of the Antibiotic Discovery Global Network

Destiny Pharma, a founding member of the BEAM (Biotechs from Europe innovating in Anti-Microbial resistance) Alliance , participated in the launch of the Antibiotic Discovery Global (ADG) Network at the Wellcome Trust in London on June 10th The ADG is a powerful coalition that aims to tackle the near empty antibiotic development pipeline due to the emergence of antibiotic resistance. ADG aims to provide an international knowledge base and infrastructure to support global antibiotic discovery and development, including the rejuvenation of older antibiotics for new uses. Jim O’Neill, chairman of the Review on Antimicrobial Resistance (AMR) gave the keynote speech at the launch of the ADG.